| |
|
Executive
Briefing - Nov 14, 2010
Challenges in the antibacterial
market
Resistance demands action
The economic environment shows signs of recovery including
encouraging signals of available venture capital. Challenges are obvious
and remain abundant. Yet challenges bring opportunity. In particular,
emerging and growing resistance pressure demands action as national and
international campaigns consider incentives for antibacterial R&D,
regulatory measurement, and influencing partnering incentives. To be successful
in the rapidly changing drug development arena requires early knowledge
of these powerful influences, market approaches, viewpoints, partnerships,
and clinical practices. Be prepared to adapt your antibacterial R&D
strategies to a volatile environment!
This Executive Briefing will focus on emerging trends and opportunities
and provide you tools to guide strategic decision making as they illuminate
influences that will make or break the success of your anti-infective
business!
We will address challenges and opportunities for partnership as well
as highlight key opportunities in the current market and forward 10 years.
We will take an in-depth look at global initiatives to advance antibacterial
drug development, national campaigns to curb resistance development, and
their consequences for current business models and strategies. We will
discuss aspects of regulatory viewpoints, likely political influences
on prescribing habits, and the ever changing competitive landscape.
| Program |
- Current market overview - facts and figures for the antibacterial
market, existing drugs and therapies
- Resistance - dominating the future of antibacterial drugs
- The new competitive landscape - 10 years and beyond
- Emerging trends - global initiatives to curb resistance and
promote antibacterial R&D, regulatory strategies
- Development & market challenges - regulatory demands and
recent experience, differentiation in a crowded market
- Success strategies - reacting to emerging trends early, attracting
investors and partners, flexible business models. Learn from company
case histories - transforming major challenges into major success.
|
| When & Where |
November 14th, 2010, 14:00 to 18:00
The day before the BIO-Europe Conference in Munich, Germany
|
| Who should attend? |
Business development professionals in the anti-infective field,
CEOs, alliance management professionals, and scientists who have
interaction with business development. As networking and discussion
is part of the event, you will benefit from the deep experience
of other attendees.
Reserve your seat now as attendance is limited!
|
| Cost |
590€ early bird registration by Sept 30th,
690€ after Sept 30th
|
| Registration |
For more information or to register, please send contact details
to utheuretzbacher@cefaia.com
|
| Ursula Theuretzbacher Ph.D |
Dr. Theuretzbacher's work to generate research portfolios, discover
and assess licensing opportunities, and develop optimal R&D
strategies in the anti-infective field has been vital to the business
success of numerous start-up and established companies. Dr. Theuretzbacher
offers an integrated approach based on scientific expertise, knowledge
of the anti-infective market, and international presence to help
her clients put in place strategy and tactics to maximize returns
on investment. An internationally sought after speaker and author,
her highly regarded textbooks, scientific articles, and reviews
accepted by leading scientific journals are significant additions
to the anti-infective frontier. As an invited speaker and professional
organization board member, Dr. Theuretzbacher actively participates
at the highest levels of the professional anti-infective communities.
|
| CEFAIA |
The Center for Anti-Infective Agents (CEFAIA) is a private independent
consulting institute that provides high-level support to both start-up
and established pharmaceutical and biotech companies worldwide in
their pursuit of anti-infective drug development and licensing programs.
Founded in 1988 by Dr. Ursula Theuretzbacher, CEFAIA has extensive
experience assisting companies to establish research portfolios,
assess in-licensing opportunities, and streamline R&D strategy.
Based in Vienna, Austria, CEFAIA has established an international
reputation as the goto specialist for antibiotics and antifungals
in science and business. Our clients include startup, as well as
mid-stage and industry leading pharmaceutical companies in Europe,
North America, and the Asia with a focus on anti-infective agents.
|
|
|
 |
